Stockpolly
Search
SCYX · NASDAQ · Medical - Pharmaceuticals

SCYNEXIS (SCYX)

Develops antifungal and rare-disease drug candidates under a GSK licensing model.

$5.30
At close+0.13 (+2.51%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue2611110101900
Cost of revenue0150000000000
Gross profit1−911110101900
1114111011991198178
Research & development61177845755124
534335443454
General & administrative000000000004
Other expenses000000000000
Operating income−10−23−10−9−10−8−9−10−811−17−8
8410−5743302−415
Interest income111111110011
Interest expense111111000000
Other non-operating income−9−4−115−7−4−3−30−24−15
Income before tax−2−191−14−3−4−5−7−912−217
Income tax expense001000000000
Net income from continuing operations−2−200−14−3−4−5−7−912−217
Net income−2−200−14−3−4−5−7−912−217
EPS, basic−$0.29−$4.21$0.07−$2.38−$0.46−$0.93−$0.87−$1.11−$1.38$2.25−$3.34$0.63
EPS, diluted−$0.29−$4.52$0.07−$2.38−$0.46−$0.93−$0.87−$1.11−$1.38$2.25−$3.34$0.63
Weighted average shares, basic6566656665612
Weighted average shares, diluted6566656665612
EBITDA−1−191−14−3−4−5−7−912−217
Depreciation & amortization000000000000
EBIT−1−191−14−3−4−5−7−912−217